Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods:: results from a population-based study of young breast cancer patients

被引:18
|
作者
Lee, Eunjung [1 ]
McKean-Cowdin, Roberta [1 ]
Ma, Huiyan [2 ]
Chen, Zhengjia [1 ,3 ]
Van Den Berg, David [1 ]
Henderson, Brian E. [1 ]
Bernstein, Leslie [4 ,5 ]
Ursin, Giske [1 ,6 ]
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA
[2] Univ So Calif, Keck Sch Med, Inst Hlth Promot & Dis Prevent Res, Alhambra, CA 91803 USA
[3] Childrens Oncol Grp, Arcadia, CA 91066 USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA
[6] Univ Oslo, Dept Nutr, N-0316 Oslo, Norway
来源
BREAST CANCER RESEARCH | 2008年 / 10卷 / 01期
关键词
D O I
10.1186/bcr1865
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Efforts are ongoing to determine the significance of unclassified variants ( UVs) in the breast cancer susceptibility genes BRCA1/ BRCA2, but no study has systematically assessed whether women carrying the suspected deleterious UVs have characteristics commonly seen among women carrying known deleterious or disease- causing mutations in BRCA1/ BRCA2. Methods We sequenced BRCA1/ BRCA2 in 1,469 population-based female breast cancer patients diagnosed between the ages of 20 and 49 years. We used existing literature to classify variants into known deleterious mutations, polymorphic variants, and UVs. The UVs were further classified as high risk or low risk based on five methods: allele frequency, Polyphen algorithm, sequence conservation, Grantham matrix scores, and a combination of the Grantham matrix score and sequence conservation. Furthermore, we examined whether patients who carry the variants classified as high risk using these methods have risk characteristics similar to patients with known deleterious BRCA1/ BRCA2 mutations ( early age at diagnosis, family history of breast cancer or ovarian cancer, and negative estrogen receptor/ progesterone receptor). Results We identified 262 distinct BRCA1/ BRCA2 variants, including 147 UVs, in our study population. The BRCA1 UV carriers, but not the BRCA2 UV carriers, who were classified as high risk using each classification method were more similar to the deleterious mutation carriers with respect to family history than those carriers classified as low risk. For example, the odds ratio of having a first- degree family history for the high- risk women classified using Polyphen was 3.39 ( 95% confidence interval = 1.16 to 9.94) compared with normal/ polymorphic BRCA1 carriers. The corresponding odds ratio of low- risk women was 1.53 ( 95% confidence interval = 1.07 to 2.18). The odds ratio for high- risk women defined by allele frequency was 2.00 ( 95% confidence interval = 1.14 to 3.51), and that of low-risk women was 1.30 ( 95% confidence interval = 0.87 to 1.93). Conclusion The results suggest that the five classification methods yielded similar results. Polyphen was particularly better at isolating BRCA1 UV carriers likely to have a family history of breast cancer or ovarian cancer, and may therefore help to classify BRCA1 UVs. Our study suggests that these methods may not be as successful in classifying BRCA2 UVs.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2using five methods: results from a population-based study of young breast cancer patients
    Eunjung Lee
    Roberta McKean-Cowdin
    Huiyan Ma
    Zhengjia Chen
    David Van Den Berg
    Brian E Henderson
    Leslie Bernstein
    Giske Ursin
    Breast Cancer Research, 10
  • [2] Breast cancer susceptibility genes -: BRCA1 and BRCA2
    Brody, LC
    Biesecker, BB
    MEDICINE, 1998, 77 (03) : 208 - 226
  • [3] BRCA1 and BRCA2– breast cancer susceptibility genes
    W. Hofmann
    P. M. Schlag
    Journal of Cancer Research and Clinical Oncology, 2000, 126 : 487 - 496
  • [4] BRCA1 and BRCA2 -: breast cancer susceptibility genes
    Hofmann, W
    Schlag, PM
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2000, 126 (09) : 487 - 496
  • [5] Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study
    Antoniou, AC
    Pharoah, PDP
    McMullan, G
    Day, NE
    Ponder, BAJ
    Easton, D
    GENETIC EPIDEMIOLOGY, 2001, 21 (01) : 1 - 18
  • [6] Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients
    Yoon, Kyong-Ah
    Park, Boyoung
    Lee, Byung Ii
    Yang, Moon Jung
    Kong, Sun-Young
    Lee, Eun Sook
    CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 627 - 634
  • [7] Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients:: A population-based study
    de Sanjosé, S
    Léoné, M
    Bérez, V
    Izquierdo, A
    Font, R
    Brunet, JM
    Louat, T
    Vilardell, L
    Borras, J
    Viladiu, P
    Bosch, FX
    Lenoir, GM
    Sinilnikova, OM
    INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (04) : 588 - 593
  • [8] BRCA1 and BRCA2 mutations in a population-based study of male breast cancer
    Victoria M Basham
    Julian M Lipscombe
    Joanna M Ward
    Simon A Gayther
    Bruce AJ Ponder
    Douglas F Easton
    Paul DP Pharoah
    Breast Cancer Research, 4
  • [9] Frequency of pathogenic variants in BRCA1 and BRCA2 genes in a Russian population-based sample and in patients with breast or ovarian cancer
    Limonova, Alena
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Skirko, Olga
    Klimushina, Marina
    Sotnikova, Evgeniia
    Kurilova, Olga
    Efimova, Irina
    Lyubchenko, Ludmila
    Filippova, Margarita
    Poloznikov, Andrey
    Kutsenko, Vladimir
    Pokrovs-Kaya, Maria
    Drapkina, Oxana
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 373 - 373
  • [10] The molecular biology of the breast cancer susceptibility genes BRCA1 and BRCA2
    Venkitaraman, AR
    JOURNAL OF PATHOLOGY, 1999, 187 : 42A - 42A